Monarch Bioimplants

Monarch Bioimplants

NeuroShield is made of naturally occurring Chitosan, which shields nerves from further damage and promotes faster regrowth. Learn more

Launch date
Market cap
-
Enterprise valuation
€80—120m (Dealroom.co estimates Sep 2020.)
Rising Sun Indiana (HQ)
  • Edit
DateInvestorsAmountRound

€20.0m

Early VC

N/A

Acquisition
Total Funding€20.0m

Recent News about Monarch Bioimplants

Edit
More about Monarch Bioimplantsinfo icon
Edit

Monarch Bioimplants specializes in developing advanced chitosan-based bioimplants designed for peripheral nerve regeneration. The company operates in the biomedical sector, focusing on creating solutions that aid in the recovery of nerve injuries. Monarch Bioimplants serves healthcare providers, particularly those involved in surgical treatments and nerve repair. The business model revolves around the research, development, and commercialization of bioimplants that are fully absorbed by surrounding tissues, minimizing side effects and enhancing patient outcomes. Revenue is generated through the sale of these specialized medical devices to hospitals and clinics. Monarch Bioimplants leverages the natural properties of chitosan, a polysaccharide known for its biocompatibility and bioabsorption, to offer innovative medical solutions. The company aims to improve the quality of life for patients suffering from nerve damage through its cutting-edge technology.

Keywords: chitosan, bioimplants, nerve regeneration, biomedical, healthcare, surgery, biocompatibility, bioabsorption, medical devices, innovation.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.